|
|
|
|
|
|
|
| |
| 28-Aug-2024 | |
Cenforce 100 India commands an impressive 38% market share in the phosphodiesterase-5 inhibitor segment, according to AIOCD AWACS data. This dominance stems from three factors: widespread availability across 92% of urban and 68% of rural pharmacies, consistent pricing between ₹650-850 per 10-tablet strip, and physician confidence developed over 12 years of domestic use. The product's distribution network covers all 739 districts through 23 authorized super-stockists.
Indian urologists report these therapeutic outcomes:
• First-dose efficacy: 79% success rate (Indian Journal of Urology, 2023)
• Mean time to erection: 32 minutes (range 25-45)
• Duration of effect: 4.8 ± 0.7 hours
• Patient satisfaction: 8.2/10 on IIEF-Q3 scale
These results match originator drug performance while costing 83% less per dose.
As a Schedule H drug in India, Cenforce 100 requires:
1. Prescription-only distribution
2. CDSCO-approved manufacturing at Centurion's WHO-GMP facilities
3. Mandatory batch testing for dissolution (≥80% in 45 minutes)
4. Temperature-controlled supply chain maintenance
Recent DCGI audits show 98.7% compliance across tested samples, outperforming many multinational equivalents.
The product's affordability revolutionizes ED treatment:
• Reaches 72% more patients than premium brands
• Included in PMJAY and 19 state health schemes
• Reduces monthly treatment cost from ₹6,000 (originator) to ₹850
This accessibility aligns with India's National Health Policy objectives for non-communicable diseases.
Innovations in progress include:
• New 56-tablet physician samples (expected Q3 2024)
• Combination packs with tadalafil for dose comparison
• Digital verification system to combat counterfeits
Market analysts project 9-12% annual growth through 2027, potentially reaching ₹2,800 crore in domestic sales.
Next analysis: Patient adherence patterns in long-term sildenafil citrate therapy